Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zenas BioPharma, Inc. ( (ZBIO) ) just unveiled an update.
On September 2, 2025, Zenas BioPharma entered into a $300 million funding agreement with Royalty Pharma, granting them rights to revenue streams from the sales of obexelimab. This deal provides Zenas with financial support to advance obexelimab’s development and potential commercial launch, particularly for treating IgG4-Related Disease, and underscores the drug’s potential as a significant player in the autoimmune disease market.
The most recent analyst rating on (ZBIO) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Zenas BioPharma, Inc. stock, see the ZBIO Stock Forecast page.
Spark’s Take on ZBIO Stock
According to Spark, TipRanks’ AI Analyst, ZBIO is a Neutral.
The overall score for Zenas BioPharma is primarily impacted by its weak financial performance, marked by revenue decline and cash flow issues. However, strong technical indicators and positive corporate events provide some optimism for future potential, despite current valuation concerns.
To see Spark’s full report on ZBIO stock, click here.
More about Zenas BioPharma, Inc.
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing and commercializing transformative therapies for autoimmune diseases. Their lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to inhibit B cell activity without depleting them, targeting diseases such as Immunoglobulin G4-Related Disease, Relapsing Multiple Sclerosis, and Systemic Lupus Erythematosus.
Average Trading Volume: 179,145
Technical Sentiment Signal: Strong Buy
Current Market Cap: $673.8M
Learn more about ZBIO stock on TipRanks’ Stock Analysis page.